JP2008531730A - Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 - Google Patents

Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 Download PDF

Info

Publication number
JP2008531730A
JP2008531730A JP2007558291A JP2007558291A JP2008531730A JP 2008531730 A JP2008531730 A JP 2008531730A JP 2007558291 A JP2007558291 A JP 2007558291A JP 2007558291 A JP2007558291 A JP 2007558291A JP 2008531730 A JP2008531730 A JP 2008531730A
Authority
JP
Japan
Prior art keywords
cells
islet
diabetes
insulin
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007558291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531730A5 (enExample
Inventor
レべタン、クラレサ、エス．
Original Assignee
キュアーディーエム、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュアーディーエム、インク． filed Critical キュアーディーエム、インク．
Publication of JP2008531730A publication Critical patent/JP2008531730A/ja
Publication of JP2008531730A5 publication Critical patent/JP2008531730A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007558291A 2005-03-04 2006-03-03 Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 Pending JP2008531730A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65896505P 2005-03-04 2005-03-04
US68208705P 2005-05-18 2005-05-18
US68481905P 2005-05-25 2005-05-25
PCT/US2006/007750 WO2006096565A2 (en) 2005-03-04 2006-03-03 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions

Publications (2)

Publication Number Publication Date
JP2008531730A true JP2008531730A (ja) 2008-08-14
JP2008531730A5 JP2008531730A5 (enExample) 2009-04-23

Family

ID=36570401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007558291A Pending JP2008531730A (ja) 2005-03-04 2006-03-03 Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物

Country Status (4)

Country Link
US (1) US8211430B2 (enExample)
EP (1) EP1858545A2 (enExample)
JP (1) JP2008531730A (enExample)
WO (1) WO2006096565A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528970A (ja) * 2015-09-16 2018-10-04 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） 悪性腫瘍を治療および／または腫瘍再発を予防するためのゲル化組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
EP2064544A1 (en) * 2006-09-14 2009-06-03 Zora Biosciences OY Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
TW200826088A (en) * 2006-12-08 2008-06-16 Lite On It Corp Optical disk drive with defocus-prohibited device
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
WO2009043468A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of corticotropin-releasing factor as a therapeutic agent
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
US20110200617A1 (en) 2008-01-18 2011-08-18 Yaron Ilan Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
RU2011113405A (ru) 2008-09-08 2012-10-20 Оттава Хоспитл Рисерч Инститьют (Ca) Регенерация поджелудочной железы, индуцированная периостином
BRPI0921230A2 (pt) * 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
CA2778331A1 (en) * 2009-10-20 2011-04-28 Aoife Brennan Methods of using anti-cd3 antibodies to prevent weight gain
WO2013128450A1 (en) * 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
US20170081375A1 (en) * 2012-10-26 2017-03-23 Claresa Levetan Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
US9321812B2 (en) * 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
US10378055B2 (en) 2015-04-08 2019-08-13 City Of Hope Methods and compositions for measuring beta cell death
AU2020271901A1 (en) * 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US12153056B2 (en) 2019-07-15 2024-11-26 Washington University Compositions for and methods of diagnosing, prognosing, and treating diabetes
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN115850486B (zh) * 2022-11-16 2023-05-30 艾可泰科(浙江)控股有限公司 胰岛干细胞在治疗糖尿病中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094958A1 (en) * 2002-05-09 2003-11-20 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
WO2003105897A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4816937A (en) * 1985-10-17 1989-03-28 Canon Kabushiki Kaisha Recording and/or reproduction apparatus capable of retaining start up information
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH01137994A (ja) 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
ATE242005T1 (de) * 1994-12-21 2003-06-15 Yeda Res & Dev P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
EP0815129B1 (en) 1995-02-22 2011-01-05 Eastern Virginia Medical School of the Medical College of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6713058B2 (en) * 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US20040132644A1 (en) 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
US7166439B2 (en) 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
US6946151B2 (en) 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094958A1 (en) * 2002-05-09 2003-11-20 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
WO2003105897A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011043985; Ｄｉａｂｅｔｅｓ Ｖｏｌ．５３，　Ｎｏ．７, 2004, ｐ．１７００-１７０５ *
JPN6011043988; 内分泌・糖尿病科 第２０巻，第１号, 20050128, ｐ．６９-７４ *
JPN6011043990; Ａｎｎａｌｓ　ｏｆ　Ｓｕｒｇｅｒｙ Ｖｏｌ．２４０，　Ｎｏ．５, 2004, ｐ．８７５-８８４ *
JPN6011043992; Ｌａｎｃｅｔ Ｖｏｌ．３５８，　Ｎｏ．９２９５, 2001, ｐ．１７４９-１７５３ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528970A (ja) * 2015-09-16 2018-10-04 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） 悪性腫瘍を治療および／または腫瘍再発を予防するためのゲル化組成物

Also Published As

Publication number Publication date
US20060198839A1 (en) 2006-09-07
WO2006096565A3 (en) 2006-12-14
US8211430B2 (en) 2012-07-03
EP1858545A2 (en) 2007-11-28
WO2006096565A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
US8211430B2 (en) Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20240100126A1 (en) Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
Haq et al. Comparative review of drugs used in diabetes mellitus—new and old
AU2012328388B2 (en) Treatment protocol of diabetes type 2
US20150086548A1 (en) Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
AU2006275424B2 (en) Method of preserving the function of insulin-producing cells
KR101983982B1 (ko) 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
KR20210024583A (ko) 요법을 위한 gip/glp1 공효능제 사용 방법
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
US11116768B2 (en) Combination treatment for the regenerative therapy of type 1 diabetes mellitus patients
CA2666846C (en) Method of restoring the incretin effect
US8895505B2 (en) Method of treatment of type 2 diabetes
Das et al. Pathophysiology and Clinical Therapeutic Aspects of Diabetes
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
HK1198577B (en) Treatment protocol of diabetes type 2
TW201302216A (zh) 第２型糖尿病患者中低血糖之預防
TW201311270A (zh) 用於改善血糖控制作為基礎胰島素附加治療之醫藥組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130521